Editorial
|
|
|
|
|
Important lessons are still being overlooked
|
|
|
|
New Products
|
|
|
|
|
A me-too neuroleptic; no panacea
|
|
|
|
|
|
|
|
|
|
|
|
Whatever the dosage, the drug should be avoided in severe persistent asthma
|
|
|
|
|
|
|
|
|
|
Company failed to supply required data
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Long-term studies are needed
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Risky in prostate cancer prevention
|
|
|
|
|
|
|
|
|
|
Inform patients of these risks
|
|
|
|
Reviews
|
|
|
|
|
Preserve quality of life
|
|
|
|
|
|
|
|
|
|
Symptoms persist longer without antibiotics
|
|
|
|
Outlook
|
|
|
|
|
Promoting a culture of safety
|
|
|
|
|
|
|
|
|
|
New drugs must be compared to established treatments
|
|
|
|
|
|
|
|